Intellia Therapeutics Gains 47% in 2026: Inside Cathie Wood's Bold Biotech Bet

Cathie Wood, the CEO of Ark Invest, has built a reputation for spotting companies with transformative potential before mainstream investors catch on. One of her firm’s marquee holdings, Intellia Therapeutics (NASDAQ: NTLA), exemplifies this contrarian approach. The mid-cap biotech firm, which specializes in gene-editing medicine development, has delivered impressive returns for early believers—with shares climbing 47% year-to-date through March 2026. Yet the question facing new investors remains: has this momentum already priced in the upside, or does the company still harbor untapped value?

Why Intellia’s Stock Is Rallying After FDA Clinical Hold Lifted

The pivotal catalyst driving Intellia’s strong performance stems from regulatory progress on its lead candidate, nex-z. Last year, the U.S. Food and Drug Administration (FDA) imposed clinical holds on two phase 3 studies following a patient death attributed to liver failure. The market punished the stock heavily during this period of uncertainty.

Fast forward to 2026: the FDA has now cleared these clinical holds, allowing Intellia to resume its late-stage trials. This represents a critical turning point. The company’s alternative treatment for transthyretin amyloidosis—a rare genetic disease causing progressive cardiac and neurological dysfunction—can now advance toward potential approval. Intellia’s other pipeline asset, lonvo-z, targets hereditary angioedema, offering hope to patients with few existing therapeutic options. The stock’s 47% surge reflects market relief that a major roadblock has been removed.

Regeneron Partnership and One-Time Treatment Advantage

Beyond the regulatory win, Intellia boasts structural advantages that caught Cathie Wood’s attention. The company’s collaboration with pharmaceutical giant Regeneron on nex-z development signals confidence from an industry heavyweight. More importantly, nex-z would represent a genuine one-and-done therapy—a single treatment potentially offering lasting benefit to the hundreds of thousands of patients worldwide living with transthyretin amyloidosis. In an industry dominated by chronic dosing regimens, this differentiation carries real commercial value.

Gene-editing medicines, however, face inherent adoption barriers. They typically command premium pricing and require complex manufacturing and administration protocols. Payers and healthcare systems remain cautious about integrating such medicines into standard treatment algorithms. These structural headwinds existed before Intellia’s regulatory stumble and persist today.

Safety Uncertainties and Market Adoption Challenges

Here’s where investor caution becomes warranted: the FDA and Intellia have never publicly disclosed whether nex-z itself caused the liver toxicity that led to the patient’s death. This ambiguity creates real risk. While Intellia will now exclude patients with pre-existing liver conditions and implement enhanced monitoring protocols in its revised trial designs, the fundamental question lingers. If nex-z carries genuine hepatotoxicity risk, further clinical setbacks could emerge despite safeguards.

Layered atop this unresolved safety question are the conventional risks any biotech faces—unexpected trial failures, regulatory pushback, manufacturing delays, and competitive threats. For a company with no approved products and no revenue, stock price volatility remains an inherent feature rather than a bug.

Is This Cathie Wood Pick Right for Your Portfolio?

Cathie Wood’s selection of Intellia reflects her thesis that transformative gene-editing medicines represent a genuine breakthrough platform. The 47% year-to-date gain suggests the market has warmed to this narrative. Yet the company’s path to commercial success remains strewn with potential obstacles.

Investors comfortable with pronounced volatility and capable of weathering further setbacks might find compelling long-term optionality here. The regulatory tailwind, the Regeneron partnership, and the one-time treatment model all present genuine upside scenarios. Conversely, conservative investors seeking stability should likely look elsewhere. The combination of unresolved safety questions, execution risks inherent to drug development, and the structural challenges facing gene-editing adoption means this remains a stock for risk-tolerant portfolios only.